Sandoz Settles for $469M. Teva Faces a Price-Fixing Trial in February

Sandoz Inc. has agreed to pay about $469 million in total to settle state claims that it helped fix generic drug prices. Teva Pharmaceutical Industries Ltd. is heading to a price-fixing trial instead. Its third-quarter 10-Q, signed on November 3, shows what waiting costs: $202 million in legal settlements and loss contingencies in one quarter, up from $60 million a year earlier.

If you buy or license generics, the verdict matters less than what the defendants do with their portfolios before it. The first trial, set for February 2027 in Hartford, covers 80 topical generics and 26 corporate defendants. That is a long list of creams, ointments and gels whose makers are now deciding which products are worth defending.

What Teva’s 10-Q says about the price-fixing trial

The states have been in court since December 2016. Teva’s filing lists three complaints against it in Connecticut, from 2016, 2019 and 2020, all sent back to Hartford in April 2024, with trial currently scheduled to begin in February 2027. In the parallel class litigation in Pennsylvania, fact discovery closed in December 2025. A July 2026 settlement in principle took the indirect reseller trial off the December calendar, Humana settled in October, and Kroger and Cigna are lined up for August 2027 and January 2028.

The allegations themselves are old-fashioned. According to the Connecticut AG, executives split customers and raised prices together, met at industry dinners and golf outings, and talked about playing nice in the sandbox. The states say some coordinated increases topped 1,000%. Teva and the others deny all of it.

Read the money lines slowly. Of the $202 million Teva booked in the quarter, $133 million was an update to the provision for one ongoing antitrust case, and $35 million was the time-value unwind on its opioid settlement. That single antitrust matter has cost $250 million in the first nine months of 2026. Teva does not say which case it is. Don’t assume.

The total reserve barely moved: $4.72 billion at September 30 against $4.75 billion at the end of 2025. It covers every open matter, opioids included, so it is not a price-fixing number. A US company books a provision only when a loss is probable and can be estimated; anything merely possible sits in the notes as text. When you size a supplier’s legal exposure, that text is often the bigger half.

The same note reads like a history of settlement-era antitrust in generics: lenalidomide, emtricitabine/tenofovir, niacin ER, lamotrigine, venlafaxine XR. If those deal structures are unfamiliar, our earlier piece on loopholes and tactics in generic approvals walks through how they were built.

Sandoz’s $469 million against Teva’s quarter

Set the two companies side by side and the trade-off is plain. Teva’s legal charges rose 3.4 times year on year. Over the same quarter its US generic revenue, biosimilars included, fell 39% to $718 million, mostly because lenalidomide capsule sales faded. The reserve on its balance sheet is now 6.6 times what its US generics business sold in those three months.

Teva’s legal charges rose 3.4× in a year while its US generic revenue fell 39%

Source: Teva Pharmaceutical Industries Form 10-Q for the quarter ended September 30, 2026. Both metrics on the same $ scale.

Sandoz took the other road. Under the October deal and earlier ones with individual states, it pays about $469 million to state enforcers. It also accepts a ten-year covenant against price-fixing, bid-rigging and market allocation, and cooperates in the cases against the companies still fighting, according to the filing summary. The deal releases Novartis AG and the Sandoz parent entities too, which the states had sued in February 2026 over alleged asset transfers.

That cooperation clause is the line Teva’s lawyers will read twice. Here is what has been agreed so far across both tracks, scaled against the single-quarter top-up Teva booked for its unnamed case.

The money flows from manufacturers to those who allegedly overpaid between May 2009 and December 2019: health plans, state programs and patients. About $172 million of the Sandoz state deal is earmarked for consumers and roughly $120 million is held for the states’ fees and costs, according to SettlementInsight’s summary of the filing.

None of this stays on the defendants’ income statements. When a generic maker carries nine-figure legal charges while its US generic sales drop 39%, every low-margin product on its list gets a second look. We have seen how fast that look ends a line: a compliance problem recently ended Baxter’s $50M cephalosporin business, and four sugammadex generics cut Merck’s quarterly sales to a fraction in one quarter.

The defense’s best argument

Teva and the other defendants deny the allegations, and nothing has been proven in court. Settlements are not admissions. The states say they hold more than 20 million documents and call records for over 600 sales and pricing staff, but volume is not proof of agreement. In a market with three or four qualified suppliers, prices can move in step without anyone picking up a phone.

The strongest case for fighting is arithmetic. Teva has already settled with a few states, Mississippi in 2021 and New Mexico and South Dakota in 2024, at roughly $1 million for each 1% of the US population. Scale that rate to the whole country and you get about $100 million, around a fifth of what Sandoz agreed to pay. Defendants also argue that states seeking restitution for consumers are chasing money the class deals already paid out. Taro made that argument in Connecticut; the attorneys general pushed back on November 4.

Our view: trial is a defensible bet for Teva’s shareholders and a poor one for anyone who needs steady supply of the topicals in the third complaint. The cooperating witnesses already exist, and trials do not grade on a curve.

Topical generics supply before a Hartford verdict

Price-fixing remedies change who makes what. Teva’s 2023 deferred prosecution agreement with the Justice Department came with a $225 million fine and a forced sale of its pravastatin business, completed in November 2024. A verdict or a consent decree in Hartford can do the same to a topical portfolio, and customers usually hear about it after the transfer is signed.

Two pricing patterns are worth expecting before February. Settling defendants live under conduct covenants and tend to get cautious about price moves in narrow markets. Defendants that fight have every reason to keep the portfolio intact until the verdict and prune afterward. In both cases, the topicals with only two or three ANDA holders are where a single exit turns into a shortage.

Five checks are worth finishing before February. None of them needs outside counsel.

Backup capacity does not have to come from the defendants. MedPharm just signed its sixth commercial topical manufacturing deal in 22 months, and a contract-made product with a clean holder history is the kind of second source you can qualify now, while nobody is in a hurry.

A company that settles is telling you its price for certainty. One that goes to trial is saying the product line is still worth a fight, or that it has not finished deciding. For a buyer of an 80-molecule topical list, the second answer is the one to plan around, because the decision gets made in Hartford and the shortage shows up in your purchase orders.